Logo

EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

Share this
EyePoint Pharmaceuticals

EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy

Shots:

  • The P-II (PAVIA) study assesses Duravyu (3mg & 2mg) vs sham for the treatment of moderately-severe to severe Non-Proliferative Diabetic Retinopathy (NPDR) patients (n=77)
  • The study showed stable or improved disease in 86% (3mg) & 80% (2mg) vs 70% of patients, 0% (3mg) & 5% (2mg) vs 10% of patients worsened ≥2-step and 5% (3mg) & 0% (2mg) vs 5% had ≥2-step improvement in DRSS score at 9mos.
  • The company plans initiation of P-III (LUGANO) trial for Duravyu in wet AMD during H2’24 along with P-III (LUCIA) for the same indication. Additionally, P-II (VERONA) study data for DME is expected in Q1’25

Ref: EyePoint Pharmaceuticals | Image: EyePoint Pharmaceuticals

Related News:- EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions